| A271 |
Clazakizumab Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection. |
|
| A272 |
Chugai SK2 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A275 |
CSTRI patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A276 |
Medarex patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A277 |
MEDI 5117 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A278 |
Merck patent anti-IL-6 Biosimilar(Anti-IL-6 / IFNb2 Reference Antibody)
Featured
|
|
|
| A129 |
Sarilumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis. |
|
| A279 |
Levilimab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid. |
|
| A280 |
APX-007 Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
|
|
| A281 |
Vobarilizumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis. |
|
| A282 |
Sapelizumab Biosimilar(Anti-IL-6Ra / CD126 Reference Antibody)
Featured
|
|
|
| A283 |
PF-06342674 Biosimilar(Anti-IL-7Ra / CD127 Reference Antibody）
Featured
|
|
|
| A284 |
Lusvertikimab Biosimilar（Anti-IL-7Ra / CD127 Reference Antibody）
Featured
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. |
|
| A285 |
Bapotulimab Biosimilar(Anti-ILDR2 Reference Antibody)
Featured
|
Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting immunoglobulin-like domain containing receptor 2 (ILDR2). Bapotulimab has antitumor and immunosuppressive effects. |
|
| A286 |
Garetosmab Biosimilar(Anti-INHBA / Activin A Reference Antibody)
Featured
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. |
|
| A287 |
Oxford Brookes U. patent anti-Activin Beta-B Biosimilar(Anti-INHBB / Activin B Reference Antibody)
Featured
|
|
|
| A288 |
Scripps patent anti-CD11a Biosimilar(Anti-Integrin a11 / ITAG11 Reference Antibody)
Featured
|
|
|
| A289 |
Etrolizumab Biosimilar(Anti-Integrin a4b7 (ITGA4 & ITGB7) Reference Antibody)
Featured
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD). |
|
| A290 |
Briakinumab Biosimilar(Anti-IL-12 (IL-12a & IL-12b) Reference Antibody)
Featured
|
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. |
|
| A291 |
Nipocalimab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody)
Featured
|
Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 and extracellular pH 7.6. |
|
| A292 |
Vatelizumab Biosimilar(Anti-Integrin a2b1 (ITGA2 & ITGB1) Reference Antibody )
Featured
|
Vatelizumab (GBR500) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). Vatelizumab can be used for the research of multiple sclerosis. |
|
| A294 |
Etaracizumab Biosimilar(Anti-Integrin aVb3 (ITGAV & ITGB3) Reference Antibody )
Featured
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer. |
|
| A295 |
Orilanolimab Biosimilar(Anti-FcRn (FCGRT & B2M) Reference Antibody)
Featured
|
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity. |
|
| DC60663 |
Si5-N14
Featured
|
Si5-N14 is a siloxane-incorporated lipid for lung-targeting mRNA delivery. The siloxane moieties enhance cellular internalization of mRNA-LNPs and improve their endosomal escape capacity, augmenting their mRNA delivery efficacy. |
|
| DC60665 |
JNJ-74856665
Featured
|
JNJ-74856665 is an orally bioavailable, potent, and selective DHODH inhibitor with IC50 of 0.40 nM. JNJ-74856665 shows favorable physicochemical properties and has been selected for clinical development in patients with AML and myelodysplastic syndromes (MDS). |
|
| DC60666 |
JAB-3312
Featured
|
JAB-3312 is a potent SHP2 allosteric inhibitor with binding Kd of 0.37 nM, enzymatic IC50 of 1.9 nM, KYSE-520 antiproliferative IC50 of 7.4 nM and p-ERK inhibitory IC50 of 0.23 nM, respectively. |
|
| DC60667 |
EDP-235
Featured
|
EDP-235 is a SARS-CoV-2 3CLpro inhibitor with potent nanomolar activity against all SARS-CoV-2 variants, as well as clinically relevant human and zoonotic coronaviruses. EDP-235 maintains potency against variants bearing mutations associated with nirmatrelvir resistance. EDP-235 demonstrates a ≥ 500-fold selectivity index against multiple host proteases. |
|
| DC60668 |
BI-9787
Featured
|
BI-9787 is a potent zwitterionic ketohexokinase inhibitor with nanomolar activity against hKHK-C, hKHK-A, mKHK-C and rKHK-C. BI-9787 shows >100-fold selectivity for all targets except PDE4D2. |
|
| DC60669 |
YD23
Featured
|
YD23 is a potent and highly selective degrader of SMARCA2. YD23 has potent tumor growth inhibitory activity in SMARCA4-mutant xenografts. |
|
| A296 |
Efalizumab Biosimilar(Anti-Integrin aL / ITGAL / CD11a Reference Antibody)
Featured
|
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research. |
|
